Mapping of catecholaminergic denervation, neurodegeneration, and inflammation in 6-OHDA-treated Parkinson’s disease mice
Abstract Efforts to develop disease-modifying treatments for Parkinson’s disease (PD) have been hindered by the lack of animal models replicating all hallmarks of PD and the insufficient attention to extra-nigrostriatal regions pathologically critical for the prodromal appearance of non-motor sympto...
Saved in:
| Main Authors: | Matteo Santoro, Rachel K. Lam, Sarah E. Blumenfeld, Weiqi Tan, Peter Ciari, Emily K. Chu, Nay L. Saw, Daniel Ryskamp Rijsketic, Jennifer S. Lin, Boris D. Heifets, Mehrdad Shamloo |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-02-01
|
| Series: | npj Parkinson's Disease |
| Online Access: | https://doi.org/10.1038/s41531-025-00872-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of noradrenergic inhibition on neuroinflammation and pathophysiology in mouse models of Alzheimer’s disease
by: Andrew K. Evans, et al.
Published: (2024-12-01) -
Tetraspanin (TSP-17) protects dopaminergic neurons against 6-OHDA-induced neurodegeneration in C. elegans.
by: Neda Masoudi, et al.
Published: (2014-12-01) -
Case Report: The unrelenting journey—successful resolution of catecholaminergic polymorphic ventricular tachycardia (CPVT) through right cardiac sympathetic denervation in a teenager after left cardiac sympathetic denervation
by: Hei-To Leung, et al.
Published: (2024-12-01) -
Afobazole prevents motor function impairment in mice with 6-OHDA induced Parkinsonism
by: I. A. Kadnikov, et al.
Published: (2019-10-01) -
Cell fate analysis of embryonic ventral mesencephalic grafts in the 6-OHDA model of Parkinson's disease.
by: Sonya Carvalho Neto, et al.
Published: (2012-01-01)